menu

Implementing LDL-C—Lowering Therapy: Conversations with the Care Team

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Implementing LDL-C—Lowering Therapy: Conversations with the Care Team

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

How can you implement/integrate LEQVIO®(inclisiran) into your clinical practice?

  • Sponsored by

  • Overview

    Explore the acquisition pathways and learn key strategies for implementing LEQVIO® (inclisiran) into your practice with Dr Michael Farbaniec, Lipid Clinic Director in Pennsylvania, Dr Emma Hegwood, a cardiology fellow with Dr Farbaniec in the Clinical World of Cardiology and also a LEQVIO patient, and Care Coordinator and Registered Nurse Brittany Heller.

    Dr Farbaniec, Dr Hegwood, and Ms Heller have all been compensated for their time.

  • INDICATION

    LEQVIO® (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

  • IMPORTANT SAFETY INFORMATION

    Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

    Please click here for LEQVIO full Prescribing Information.

    10/23      311289

Schedule19 Apr 2024